Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia

Vaccine

Volumn 26, Issue 36, 2008, Pages 4669-4675

  Köchling, Joachim ^a,b,c   Prada, Javier ^b   Bahrami, Masoud ^c   Stripecke, Renata ^d   Seeger, Karl ^b   Henze, Günter ^b   Wittig, Burghardt ^b,e   Schmidt, Manuel ^e  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MOLOGEN AG   (Germany)

Author keywords

DNA vaccination; Ph+ ALL; Syngeneic mouse model

Indexed keywords

BCR ABL PROTEIN; DNA VACCINE; DOUBLE STEM LOOP IMMUNOMODULATOR; GENE THERAPY AGENT; GOLD; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MINIMALISTIC IMMUNOGENIC DEFINED CONTENT VECTOR FOR GENE EXPRESSION;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE GUN IMMUNIZATION; LEUKEMIA RELAPSE; MOUSE; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SURVIVAL RATE;

EID: 48649102652     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.094     Document Type: Article

References (38)

1. Solomon E., Borrow J., and Goddard A.D. Chromosome aberrations and cancer. Science 254 (1991) 1153-1160
2. Look A.T. Oncogenic transcription factors in the human acute leukaemias. Science 278 (1997) 1059-1064
3. Beyermann B., Agthe A.G., Adams H.P., Seeger K., Linderkamp C., Goetze G., et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukaemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 87 (1996) 1532-1538
4. Arico M., Valsecchi M.G., Camitta B., Schrappe M., Chessells J., Baruchel A., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. N Engl J Med 342 (2000) 998-1006
5. Hirano N., Takahashi T., Ohtake S., Hirashima K., Emi N., Saito K., et al. Expression of costimulatory molecules in human leukaemias. Leukaemia 10 (1996) 1168-1176
6. Schwartz R.H. A cell culture model for T lymphocyte clonal anergy. Science 248 (1990) 1349-1356
7. Matulonis U.A., Dosiou C., Lamont C., Freeman G.J., Mauch P., Nadler L.M., et al. Role of B7-1 in mediating an immune response to myeloid leukaemia cells. Blood 85 (1995) 2507-2515
8. Arceci R.J. The potential for antitumor vaccination in acute myelogenous leukaemia. J Mol Med 76 (1998) 80-93
9. Stripecke R., Skelton D.C., Pattengale P.K., Shimada H., and Kohn D.B. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukaemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukaemia. Hum Gene Ther 10 (1999) 2109-2122
10. Köchling J., König-Merediz S.A., Stripecke R., Buchwald D., Korte A., von Einsiedel H.G., et al. Protection of mice against Ph+ acute lymphoblastic leukaemia by cell-based vaccination using non-viral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin Can Res 9 (2003) 3142-3149
11. Ciernik I.F., Berzofsky J.A., and Carbone D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156 (1996) 2369-2375
12. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
13. Liu M.A. DNA vaccines: a review. J Int Med 253 (2003) 402-410
14. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
15. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., and Falo Jr. L.D. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2 (1996) 1122-1128
16. Conry R.M., Widera G., LoBuglio A.F., Fuller J.T., Moore S.E., Barlow D.L., et al. Selected strategies to augment polynucleotide immunization. Gene Ther 3 (1996) 67-74
17. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
18. Jakob T., Walker P.S., Krieg A.M., Udey M.C., and Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161 (1998) 3042-3049
19. Schmidt M., Nagel S., Proba J., Thiede C., Ritter M., Waring J.F., et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukaemias. Blood 91 (1998) 22-29
20. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., and Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94 (1997) 10833-10837
21. Stripecke R., Skelton D.C., Gruber T., Afar D., Pattengale P.K., Witte O.N., et al. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukaemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 9 (1998) 2049-2062
22. Schakowski F., Gorschlüter M., Junghans C., Schroff M., Buttgereit P., Ziske C., et al. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3 (2001) 793-800
23. Choi Y., Jeon Y.H., Kang J.H., Chung J.K., Schmidt M., and Kim C.W. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-γ+ T cells and enhances protective antitumor immunity. Int J Cancer 120 (2007) 1942-1950
24. McLaughlin J., Chianese E., and Witte O.N. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 9 (1989) 1866-1874
25. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63 (2003) 394-399
26. Grimm C.F., Ortmann D., Mohr L., Michalak S., Krohne T.U., Meckel S., et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterol 119 (2000) 1104-1112
27. Han R., Cladel N.M., Reed C.A., Peng X., Budgeon L.R., Pickel M., et al. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 74 (2000) 9712-9716
28. Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., et al. Dendritic cells stimulate the expansion of BCR-ABL specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukaemia. Blood 91 (1998) 977-983
29. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A., et al. Specific human cellular immunity to BCR-ABL oncogene-derived peptides. Blood 87 (1996) 3587-3592
30. Yotnda P., Firat H., Garcia Pons F., Garcia Z., Gourru G., Vernant J.P., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukaemia. J Clin Invest 101 (1998) 2290-2296
31. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J., et al. Vaccination of patients with chronic myelogenous leukaemia with BCR-ABL oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 (2000) 1781-1787
32. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25 (2007) 2546-2553
33. Young M.R., Wright M.A., and Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 159 (1997) 990-996
34. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., and Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18 (2007) 226-232
35. Messina J.P., Gilkeson G.S., and Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 147 (1991) 1759-1764
36. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12 (1994) 991-1045
37. Brown B.D., and Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood 100 (2002) 1133-1140
38. Schmidt M., Anton K., Nordhaus C., Junghans C., Wittig B., and Worm M. Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 61 (2006) 56-63